Current SP appreciation, page-259

Im with you Avemaria, I think the odds are much better than 50/50. Its a re-purpose drug that has already been approved for other applications. So the unknown is will the results stack up in the phase 3 trials? Im guessing unless American biology is completely different to Australians you would think the results will hold. We have more than 600 Aussies in the SAS program that attest to it, various DR's and OA specialists that love it and have seen the results first hand. I also don't think a prominent American OA Specialist is going to sell his soul for a $ just to promote a drug that does not work and irreparably damage his reputation.
I think the ultimate risk is that it may take a little longer and the "process" more arduous but PR is at least putting the right people to mitigate that. If they don't get revenue's in the short term the longer term risk may be they have to go back to market for another capital raising thus diluting our holdings.